[HTML] mdpi.com

[HTML][HTML] Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling

S Takahashi, R Noro, M Seike, C Zeng… - International journal of …, 2021 - mdpi.com
(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …
被引用次数：28 相关文章

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.

S Takahashi, R Noro, M Seike, C Zeng… - … Journal of Molecular …, 2021 - europepmc.org
Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …
[PDF] archive.org

[PDF][PDF] Long Non-Coding RNA CRNDE is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng, M Matsumoto… - scholar.archive.org
Introduction: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable challenge for many clinical oncologists. The …
[HTML] nih.gov

[HTML][HTML] Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng… - … Journal of Molecular …, 2021 - ncbi.nlm.nih.gov
Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …
[PDF] semanticscholar.org

[PDF][PDF] Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng… - Int. J. Mol …, 2021 - pdfs.semanticscholar.org
(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng… - International …, 2021 - search.proquest.com
Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng, M Matsumoto… - 2021 - agris.fao.org
(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …

Long Non-Coding RNA CRNDE is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike, C Zeng, M Matsumoto… - 2021 - researchsquare.com
Introduction: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable challenge for many clinical oncologists. The …

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling.

S Takahashi, R Noro, M Seike, C Zeng… - International …, 2021 - search.ebscohost.com
Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

S Takahashi, R Noro, M Seike… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The …